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Abstract
Objective: We sought to evaluate whether differences in rates of contraceptive discontinuation exist among
black and white women receiving contraceptive counseling and no-cost contraception among users of long-
acting reversible contraceptive (LARC; intrauterine devices or subdermal implant) and non-LARC (oral con-
traceptive pills, contraceptive vaginal ring, patch, or injection) methods.
Materials and Methods: We analyzed data from a prospective cohort study of 7546 non-Hispanic black and white
women who participated in the Contraceptive CHOICE Project. Among women who initiated their method within
12 weeks of enrollment, discontinuation was defined as any break in use longer than 1 month. Using Cox
proportional hazards regression analysis, we estimated discontinuation stratified by use of LARC methods.
Results: There were no statistically significant differences in contraceptive discontinuation between black and
white women at 12, 24, or 36 months among both LARC [12-month adjusted hazard ratio (HRadj-12M) 1.01
(95% confidence interval or 95% CI 0.86–1.18); HRadj-24M 1.10 (95% CI 0.97–1.24); and HRadj-36M 1.10 (95%
CI 0.98–1.23)] and non-LARC users [HRadj-12M 1.08 (95% CI 0.92, 1.26); HRadj-24M 1.07 (95% CI 0.94, 1.23);
and HRadj-36M 1.08 (95% CI 0.95, 1.23)] adjusting for confounders. Secondary analyses found no significant
differences in discontinuation of LARC and non-LARC methods among black and white women at highest risk
of pregnancy or those receiving public assistance at baseline.
Conclusions: At 12, 24, and 36 months there were no differences in contraceptive discontinuation of both
LARC methods and non-LARC methods when comparing white and black women.
Keywords: race, long-acting reversible contraception, family planning, discontinuation
Introduction
Unintended pregnancy results in long-term adverseeconomic, health, and social consequences for society,
women, and their families.1–3 Despite this, almost half of
pregnancies in the United States annually are unintended.4,5
While the percentage of unintended pregnancies has de-
creased among both white and black women between 2008
and 2011 (from 42% to 38% and from 69% to 64%, respec-
tively), it is far higher among black women (64%).5,6 Black
women have unintended live birth rates twice that of white
women (37% vs. 18%).7 Use of the most effective methods of
contraception, particularly long-acting reversible contraceptive
(LARC) methods like intrauterine devices and subdermal
implants, may dramatically reduce both the rate of unin-
tended pregnancy and its economic burden,8,9 yet significant
barriers to use of the most-effective contraceptive methods
persist.10
Prior studies have documented clear differences in the
contraceptive methods used by black and white women. Data
from the 1995 and 2006–2010 waves of the National Survey
of Family Growth (NSFG) found that while no differences in
use of highly effective contraceptives among black and white
women were evident in 1995, a significantly lower percent of
black women than white women were using highly effec-
tive contraception in 2006–2010.11 Dehlendorf extended this
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evaluation of 2006–2010 NSFG data and ascertained that
black women had lower use of both moderately and highly
effective contraceptive methods compared with their white
counterparts.12 Differences in contraceptive use have been
observed in settings designed to minimize barriers to effec-
tive contraceptive use; the California Family Planning, Access,
Care, Treatment (PACT) program, which provides free family
planning services to low-income women, found that black
women were less likely to receive intrauterine devices and
more likely to receive injectable contraception, barrier meth-
ods, and emergency contraception than white women.13
Barriers to continuation of contraception include cost, ac-
cess to clinical care, and availability of pharmacy services. The
Contraceptive CHOICE Project sought to reduce barriers to
contraceptive use primarily via access to no-cost contraception,
but also via access to ongoing clinical care and support and
pharmacy services. Previous CHOICE analyses have docu-
mented that black women were as likely as white women to
choose the most effective methods of contraception in this
setting,14,15 but it is not clear whether these methods were
continued long term. Prior analyses of racial differences in
contraceptive discontinuation have been mixed; most, but not
all, have found higher rates of discontinuation among black
women.16–23 We hypothesized that previously observed dif-
ferences in contraceptive discontinuation were attributable to
barriers to care and service that differentially affect black wo-
men. In this analysis, we examined whether there were sig-
nificant differences in discontinuation between black and white
women stratified by use of long- and short-acting contraceptive
methods which have different barriers to continuation.
Materials and Methods
The Contraceptive CHOICE Project was a prospective
cohort study of contraceptive selection and discontinuation
that enrolled 9256 St. Louis area women between August
2007 and September 2011. A summary of CHOICE methods
is provided below, and a more detailed description is pub-
lished elsewhere.24,25 In brief, CHOICE provided each par-
ticipant with contraceptive counseling and their choice of
contraception for the duration of their study participation
(2–3 years); this included no cost for refills, injections, or
device removal. The counseling used a structured model
that included information on all reversible Food and Drug
Administration-approved contraceptive methods and high-
lighted the issue of contraceptive effectiveness or the number
of pregnancies prevented among 100 typical users in 1 year.26
Counseling was provided at the initial study visit before the
selection of contraceptive method.
Participants were women between the ages 14 and 45 years
who wanted to delay pregnancy27–29 for 1 year or longer at
enrollment. Women who were not at risk for pregnancy
(history of hysterectomy or tubal ligation), not sexually ac-
tive, or not interested in reversible contraception were ex-
cluded. At enrollment participants completed a detailed
intake interview, received contraceptive counseling, had a
clinical assessment with a CHOICE-affiliated provider, and
received the contraceptive method of their choice (or ap-
propriate bridge method for women not eligible for imme-
diate start). Follow-up interviews included questions on
contraceptive use, discontinuation and satisfaction, and re-
productive outcomes.
Contraceptive continuation was defined as continuous use
of the chosen LARC or non-LARC method at 12, 24, and 36
months among women who started their contraceptive
method within 3 months of enrollment. LARC methods in-
cluded the levonorgestrel intrauterine system, the copper
intrauterine contraceptive, and the etonogestrel subdermal
implant. Non-LARC methods included oral contraceptive
pills, vaginal ring, contraceptive patch, and depot medrox-
yprogesterone acetate injection. Given that the recommended
duration of use of the etonogestrel implant was 36 months
from the date of insertion, all observations were censored at
36 months. Discontinuation was defined as any stop of 1
month or longer and was determined primarily by self-report
assessed via telephone follow-up at 3 months and then every
6 months starting at 6 months. Method use information was
supplemented by pharmacy refill logs and study clinic data
that tracked device removals or expulsions.28 Participants
that became pregnant or were lost to follow-up were censored
at the time of pregnancy and last observation, respectively.
Of the 8419 participants with discontinuation data, we ex-
cluded 654 women who reported a race other than African
American or black or Caucasian/white and 219 Hispanic
women. The final analytic sample included 7546 women
which represented 82% of the CHOICE cohort and 90% of
participants with discontinuation data.
Analyses included chi-square and Wilcoxon rank-sum
tests to evaluate racial differences in LARC use and other
important covariates (Table 1). Potential confounders in-
cluded age, highest level of education, self-reported monthly
income, insurance (none, private, or public), current receipt
of public assistance, trouble paying for basic necessities,
parity, history of unintended pregnancy, sexually transmitted
infection (STI) at time of enrollment, told by healthcare
provider that had an STI, and number of sexual partners
(lifetime). Other variables evaluated, but found to not be
confounding, included enrollment site, body mass index,
gravidity, history of abortion, age of menarche, age of first
sex, number of sexual partners in the past month, and tobacco
use (data not shown). Eleven recruitment sites were included
in adjusted analyses; however, sites with small enrollments
were collapsed in Table 1 to protect confidentiality. Con-
founding was assessed for association with black race using
logistic regression and for association with time to contra-
ceptive discontinuation using Cox proportional hazards re-
gression stratified by LARC use.
We estimated the proportion of participants who dis-
continued within 36 months of contraceptive initiation
through the construction of Kaplan–Meier survival curves.
Given that the barriers differ for LARC and non-LARC
methods, analyses of racial differences were stratified by
LARC use. We also estimated the discontinuation rate per
100 woman years using the Stata function, stptime, based on
the approach described by Clayton and Hills.30 Crude and
adjusted hazard rate ratios were estimated for the association
of black race with contraceptive discontinuation stratified by
contraceptive method duration of effectiveness using Cox
proportional hazards regression. Variables significantly as-
sociated with both race and discontinuation (a £ 0.05) and
study enrollment site were included in adjusted Cox pro-
portional hazards regression models (Table 2).
Due to the potential influence of residual confounding by
socioeconomic status and of unmeasured confounders on our















































Table 1. Sociodemographic, Sexual, and Health Characteristics at Enrollment
of Non-Hispanic Black and White Women in the Contraceptive CHOICE Project by Initial
Contraceptive Method and Race, N = 7546




pN = 901 N = 1157 N = 2500 N = 2988
Age (years) N (col%) N (col%) N (col%) N (col%)
14–19 119 (13) 224 (19) <0.001 240 (10) 542 (18) <0.001
20–24 440 (49) 444 (38) 914 (37) 1040 (35)
25–29 244 (27) 290 (25) 797 (32) 712 (24)
30 and older 98 (11) 199 (17) 549 (22) 694 (23)
Education
£High school 178 (20) 452 (39) <0.001 636 (25) 1240 (42) <0.001
Some college 369 (41) 536 (46) 932 (37) 1404 (47)
College degree or more 353 (39) 169 (15) 931 (37) 343 (11)
Public assistancea
No 815 (90) 684 (59) <0.001 1998 (80) 1308 (44) <0.001
Yes 86 (10) 471 (41) 500 (20) 1678 (56)
Insurance
Not reported 9 (1) 16 (1) <0.001 5 (<1) 26 (1) <0.001
None 335 (37) 628 (54) 877 (35) 1186 (40)
Private 529 (59) 384 (33) 1430 (57) 960 (32)
Public 28 (3) 129 (11) 188 (8) 816 (27)
Parity
0 726 (81) 579 (50) <0.001 1475 (59) 825 (28) <0.001
1 107 (12) 310 (27) 489 (20) 948 (32)
2 47 (5) 164 (14) 383 (15) 699 (23)
3 or more 21 (2) 104 (9) 153 (6) 516 (17)
Number of unintended pregnancies
0 575 (63) 401 (34) <0.001 1155 (46) 625 (21) <0.001
1 198 (23) 346 (30) 640 (26) 826 (28)
2 71 (8) 198 (17) 345 (14) 649 (22)
3 or more 56 (6) 209 (18) 357 (14) 883 (30)
Sexual partners in a lifetime
0–3 271 (31) 328 (29) <0.001 629 (25) 789 (27) <0.001
4–5 139 (16) 269 (24) 384 (16) 748 (25)
6–7 113 (13) 177 (15) 312 (13) 431 (15)
8–12 164 (19) 211 (18) 536 (22) 553 (19)
>12 182 (21) 158 (14) 609 (25) 437 (15)
History of STIb
No 693 (77) 572 (49) <0.001 1767 (71) 1409 (47) <0.001
Yes 207 (23) 585 (51) 733 (29) 1577 (53)
Current STIc
No 839 (98) 937 (87) <0.001 2395 (98) 2462 (88) <0.001
Yes 16 (2) 143 (13) 55 (2) 329 (12)
Enrollment site
University clinic 780 (87) 864 (75) <0.001 1892 (76) 2038 (68) <0.001
Community partner 1 (2 sites) 83 (9) 190 (16) 384 (15) 604 (20)
Community partner 2 (4 sites) 14 (2) 34 (3) 161 (6) 133 (4)
Community partner 3 13 (1) 28 (2) 37 (1) 108 (4)
Community partner 4 5 (1) 12 (1) 16 (1) 65 (2)
Community partner 5 6 (1) 29 (3) 10 (<1) 40 (1)
aReceipt of public assistance: unemployment; temporary assistance for needy families; income-based supplemental nutrition assistance;
or supplemental nutrition assistance for women, infants, and children.
bHistory of STI: Ever told by a healthcare provider that had one of the following STIs: chlamydia, gonorrhea, trichomoniasis, syphilis,
human papillomavirus or genital warts, human immunodeficiency virus, or herpes.
cCurrent STI: Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis.
















































findings, we performed secondary stratified analyses across
three variables as follows: receipt of public assistance, in-
surance status (uninsured, private, or public), and estimated
risk for unintended pregnancy. Stratified Kaplan–Meier
curves comparing black and white discontinuation were es-
timated by LARC use and compared using log-rank tests.
Unintended pregnancy risk was estimated using a propensity
score technique.31 Specifically, we calculated the estimated
risk of history of abortion, a proxy measure of unintended
pregnancy, using a logistic regression technique with history
of abortion as the outcome and potential confounders de-
scribed in Table 1 and the number of unintended pregnancies
as dependent variables. The estimated probability of unin-
tended pregnancy ending in abortion was categorized as low
risk (£ median of 22.3%) or high risk.
While the current analyses were secondary and based on
previously collected data, we estimated power for a non-
inferiority study to test our hypothesis that discontinuation did
not differ among black women. Our power calculations as-
sumed a noninferiority margin of 0.15, a true estimate of effect
of 1.1, and an a of 0.05.32 Based on these assumptions and
available data, the current analyses had 74% (non-LARC) to
98% (LARC) power. All statistical analyses were completed
using Stata (version 13; StataCorp LP, College Station, TX).
Results
This analysis of 7546 CHOICE participants included 3401
non-Hispanic white (45%) and 4145 non-Hispanic black
women (55%). Selection of LARC methods was comparable
in both groups (73.5% and 72.1%, p = 0.17), but black par-
ticipants had a higher rate of history of LARC use at en-
rollment (5.2% vs. 3.7%, p = 0.002). There were significant
differences in sociodemographic, sexual, and health charac-
teristics between white and black participants (Table 1). In
both the LARC and non-LARC groups, black women were
younger, more likely to only have a high school education or
less, more likely to have lower income or report financial
difficulty (public assistance or trouble paying for basic ne-
cessities), and were more likely to be uninsured or on public
insurance compared to white women. Moreover, black wo-
men reported higher rates of reproductive outcomes (preg-
nancy, live birth, unintended pregnancy, and abortion) and
current and past STI and earlier age at first sexual intercourse.
Black women reported fewer lifetime sexual partners than
white women, and there was no significant difference in the
median number of sexual partners in the past month reported
by black and white women.
Differences in the percent of black and white women who
discontinued were lower among LARC users ranging from
1.6% to 5.9% and increased with increasing duration of use
(Fig. 1). Differences in the percent discontinued among black
and white non-LARC users ranged from 5.7% to 6.8% and
did not display evidence of a temporal trend. Discontinuation
was highest in the first year of use for both black and white
women when examined in discrete annual intervals (0–12
months, 12–24 months, and 24–36 months). While discon-
tinuation rates were modestly higher among black women
for all methods and time intervals, the confidence intervals
overlapped for all comparisons among black and white ex-
cept for LARC discontinuation between 12 and 24 months.
While black women using LARC and non-LARC methods
had higher rates of contraceptive discontinuation at 36 months
in unadjusted analyses (Table 2), there were no clinically
meaningful or statistically significant differences between
adjusted rates of discontinuation for LARC and non-LARC
methods for black women compared to white women. In Cox
proportional hazards regression models adjusting for age,
education, receipt of public assistance, insurance, history of
STI, and enrollment site, discontinuation rates among black
women were higher, but not significantly so, at all three time
points (12, 24, and 36 months) for both LARC and non-
LARC methods (Fig. 2). Findings at 24 and 36 months were
within the noninferiority margin indicating no difference in
discontinuation between black and white women.
Due to the potential influence of unmeasured confounding
by factors relating to underlying risk of unintended pregnancy,
we also performed a propensity score-based stratified analysis
and compared differences in contraceptive discontinuation
among black and white women with a median or less risk of
pregnancy to those with greater than median risk of pregnancy.
The overall median estimated probability of pregnancy was
22.3%. Among women with a greater than median risk, there
were no significant differences among black and white in dis-
continuation among women with the highest risk of pregnancy
[LARC: hazard ratio (HR) 1.11, 95% confidence interval (95%
CI) 0.95–1.8 and non-LARC: HR 1.17, 95% CI 0.97–1.43].
Finally, black participants were more likely to have lower
socioeconomic position. We performed analyses stratified by
receipt of public assistance and insurance status to examine
whether differences existed among black and white eco-
nomically vulnerable women in the cohort. Discontinuation
rates at 36 months among black women who selected a non-
LARC method did not differ from their white peers who
reported public assistance at baseline among both LARC
[HRadj-assistance 1.15, 95% CI (0.94–1.41); HRadj-no assistance
Table 2. Crude and Adjusted Hazard Rate Ratios for Contraceptive Discontinuation
Comparing Black and White Women in the Contraceptive CHOICE Project
LARC methods Non-LARC methods
Crude HRR (95% CI) Adjusteda HRR (95% CI) Crude HRR (95% CI) Adjusteda HRR (95% CI)
12 months 1.13 (0.98–1.30) 1.01 (0.86–1.18) 1.20 (1.05–1.38) 1.08 (0.92–1.26)
24 months 1.21 (1.08–1.34) 1.10 (0.97–1.24) 1.17 (1.04–1.31) 1.07 (0.94–1.23)
36 months 1.22 (1.11–1.35) 1.10 (0.98–1.23) 1.17 (1.05–1.31) 1.08 (0.95–1.23)
Compared to a reference group of White non-Hispanic women.
aAdjusted for age group, education, current receipt of public assistance, insurance, history of STI, and site of enrollment.
95% CI, 95% confidence interval; HRR, hazard rate ratios.















































1.06, 95% CI (0.92–1.23)] and non-LARC users [HRadj-assistance
1.14, 95% CI (0.83–1.56); HRadj-no assistance 1.07, 95% CI
(0.92–1.23)] after adjusting for age, education, insurance status,
history of STI, and study enrollment site. Of note, there were no
significant differences in discontinuation rates comparing black
to white women stratified by insurance status.
Discussion
This analysis found similar rates of contraceptive discon-
tinuation among black and white women enrolled in the
Contraceptive CHOICE Project. After adjustment for po-
tential confounders, there were no statistically significant
FIG. 2. Survival curves
over 36 months for contra-
ceptive discontinuation com-
paring black and white
women in the Contraceptive
CHOICE Project.
FIG. 1. Discontinuation of selected contraceptive method at 12, 24, and 36 months by long-acting reversible method and
race. p-value estimated via log-rank test. 95% CI, 95%, confidence interval; LARC, long-acting reversible contraceptive.















































differences in rates of discontinuation among both LARC and
non-LARC users at 12, 24, and 36 months. Moreover, the
stratified analyses detected no significant differences among
many subgroups at traditionally high risk, including black
and white women with the highest risk of unintended preg-
nancy and those receiving public assistance.
Relatively few studies have examined the association of
race on contraceptive discontinuation for black and white
women. A recent retrospective cohort study of intrauterine
device users examined discontinuation over a period of
5 years and found that black women had higher rates of
discontinuation than white women in adjusted analyses (HR
1.31, 95% CI 1.03–1.67).17 A small study of discontinuation of
the copper intrauterine device found that while black women
had rates of 6 months discontinuation 2.3 times higher than
non-black, non-Hispanic participants, this difference was not
statistically significant.23 A study of levonorgestrel intrauterine
system users examined discontinuation among patients seen
and not seen for follow-up at an academic clinic in an urban
medical center. Among women not seen for follow-up, the rate
of discontinuation among black women was higher, but not
statistically different from that of white women (HR 1.30, 95%
CI 0.93–1.82). Among patients that were seen, black women
had rates lower, but again not statistically different from those
of white women (HR 0.66, 95% CI 0.36–1.18).33 Finally, an
examination of 24 months contraceptive discontinuation data
from CHOICE participants found a modest difference in dis-
continuation rates for black women compared to white, but did
not stratify by use of LARC methods, which have markedly
lower discontinuation rates.15,27
Multiple studies of non-LARC methods have found signifi-
cantly higher rates of discontinuation among black women,20–22
but not all,16 and there is some evidence that black women may
be more likely to discontinue pill use due to dissatisfaction than
white women.34 An early analysis of data from CHOICE ex-
amined differences in the 12-month discontinuation rates by
race among 1452 users of oral contraception (OC), patch, or
ring and found that black women were more likely to dis-
continue their method than white women (HR 1.21, 95% CI
1.02–1.44) after adjustment for marital status, receipt of public
assistance, and prior use of the method.20 However, this pre-
vious analysis included a lower risk cohort,25 incomplete out-
come ascertainment for the hardest to reach participants, and
included black Hispanic and white Hispanic women in the
comparisons. In a study comparing text reminders as a support
for OC continuation, black women were twice as likely as white
women to discontinue use by 6 months after adjusting for in-
tervention, age, age of first intercourse, history of pregnancy,
and prior use of OCs.21 Similarly, black adolescents may have
higher rates of discontinuation of injectable methods,22 but
findings are not consistent across studies.35 In contrast, similar
to our findings, Raine examined non-LARC method discon-
tinuation in a cohort of young women (ages 15–24 years) and
did not find a significant increase in risk of discontinuation at
12 months for black women, compared to white.16
The potential influence of attitudes about contraception
and concern about side effects on discontinuation in an en-
vironment with contraceptive counseling and minimal bar-
riers to method selection and continuation has not been
established. Black and white women have similar attitudes
regarding preventing unintended pregnancy.36,37 Yet, key dif-
ferences have been documented in ‘‘pregnancy fatalism’’—the
belief that the use of birth control does not matter and ‘‘when
it is your time to get pregnant, it will happen.’’38 Further-
more, experiences of side effects during use may also dif-
ferentially impact discontinuation. Guzzo and Hayford38
found that black women were significantly more concerned
about potential side effects of contraceptive methods, in-
cluding reduced sexual desire and serious health problems,
while Callegari et al.37 found that black women have more
concerns about using contraception with hormones, effec-
tiveness in preventing STI, and that a contraceptive method
does not interrupt sex.
Key barriers to LARC use have been identified as cost,
provider related (continuing education on method safety and
eligibility, device-specific training, work setting), and re-
source related (availability of contraceptive counseling and
devices)39,40; while barriers for non-LARC methods include
insurance coverage, cost, difficulty obtaining or refilling pre-
scriptions, challenges getting an appointment or getting to a
clinic, and required physical examination.41 CHOICE strove to
minimize barriers to contraceptive continuation through a
number of mechanisms: no-cost contraception, support for
prescription refills that include collaboration with a regional
pharmacy chain and reimbursement of out-of-pocket costs,
access to the study clinic for ongoing care, support, and when
needed, device removals, and the option to switch methods.
Given the structural inequalities endemic in American
society, the effect of black race may be challenging to dis-
entangle from external economic stratification where pre-
disposing factors (low income, less education, lack of access
to healthcare, and health insurance) may be concentrated in
certain populations.42,43 To better understand the role of fi-
nancial considerations on rates of discontinuation, we con-
ducted additional analyses stratified by receipt of public
assistance at enrollment and by insurance status. These ana-
lyses confirmed our primary finding and found no statisti-
cally significant differences in discontinuation among black
and white women receiving public assistance or with health
insurance.
Strengths of this analysis include stratification by LARC
method use, large sample size, a well-characterized cohort
that has been compared to state and national reproductive-
aged populations,44 and a long duration of follow-up which
permits assessment of differences at 12, 24, and 36 months.
One limitation of our analysis is our inability to rule-out
residual confounding, even with the use of propensity score
analyses. Confounding due to unmeasured factors influenc-
ing both initial method selection and discontinuation may
persist. Furthermore, it is difficult to disentangle the complex
interactions between race and socioeconomic position in an
observational analysis. Although the current findings may be
limited in generalizability, the CHOICE cohort is similar to
state and national populations with regards to use of multiple
contraceptive methods.44
Conclusions
Our research suggests that the dual interventions provided
by CHOICE—evidence-based contraceptive counseling and
no-cost contraception—may serve as an important strategy
for the reduction of disparities in contraceptive discontinua-
tion. The CHOICE interventions were patient centered and
augmented by approaches to minimize barriers in access to















































care through the establishment of a contraceptive home,
support for quick start of hormonal methods and same-day
insertion of intrauterine devices, and a partnership with a
regional pharmacy to facilitate receipt of refillable methods.
After CHOICE began the Affordable Care Act (ACA) which
greatly expanded coverage of family planning services.
While we cannot assume continuation of the ACA’s current
levels of coverage, studying this period of expanded coverage
will allow us to study the effect of no-cost contraception on
race-specific differences in contraception use and discontin-
uation at the population level across the United States.
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